Omeros Co. (NASDAQ:OMER) Receives $22.50 Consensus Target Price from Analysts

Shares of Omeros Co. (NASDAQ:OMER) have earned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $22.50.

A number of equities analysts have commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, February 20th.

Hedge Funds Weigh In On Omeros

A number of large investors have recently added to or reduced their stakes in OMER. Barclays PLC grew its stake in shares of Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares during the last quarter. State Street Corp grew its position in Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares during the last quarter. HighTower Advisors LLC increased its stake in Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 4,000 shares during the period. Wellington Management Group LLP bought a new stake in Omeros in the third quarter valued at approximately $305,000. Finally, MML Investors Services LLC boosted its stake in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Trading Up 7.1 %

Shares of OMER opened at $8.42 on Friday. The stock has a 50-day moving average price of $8.80 and a 200-day moving average price of $7.15. The company has a market cap of $487.94 million, a PE ratio of -3.65 and a beta of 2.03. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.